Adverum Biotechnologies Completes IND Amendment And Prepares To Initiate The Phase 2 LUNA Trial Of ADVM-022 In Wet AMD
- Cash runway extended into 2025 due to corporate restructuring to prioritize the clinical development of ADVM-022 and provide additional resources beyond anticipated one-year topline results of the Phase 2 LUNA trial
-